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Abstract
Congenital anomaly registries have two main surveillance aims: firstly to define baseline epidemiology of important congenital
anomalies to facilitate programme, policy and resource planning, and secondly to identify clusters of cases and any other
epidemiological changes that could give early warning of environmental or infectious hazards. However, setting up a sustainable
registry and surveillance system is resource-intensive requiring national infrastructure for recording all cases and diagnostic
facilities to identify those malformations that that are not externally visible. Consequently, not all countries have yet established
robust surveillance systems. For these countries, methods are needed to generate estimates of prevalence of these disorders which
can act as a starting point for assessing disease burden and service implications. Here, we describe how registry data from high-
income settings can be used for generating reference rates that can be used as provisional estimates for countries with little or no
observational data on non-syndromic congenital malformations.
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Abbreviations
CHD Congenital Heart Disease
EUROCAT European Survei l lance of Congenital
Anomalies and Twins
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NSCM Non-syndromic congenital malformations
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Introduction
TheModell Database of Congenital Disorders (MGDb) uses a
set of defined methods to relate demographic data to known
birth prevalence of selected groups of congenital disorders, in
order to generate estimates relevant to public health, policy-
making and clinical practice (Modell et al. 2016; Moorthie et
al. 2017). We use the term baseline birth prevalence to refer to
the prevalence of the disorder among all births (i.e. livebirths
plus stillbirths) that would occur in the absence of any inter-
vention. This provides the starting point for modelling the
current and future prevalence of these disorders as it provides
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an Benvelope^ into which all outcomes must fit (Moorthie et
al. 2017).
The existence of long-standing congenital anomaly regis-
tries has the advantage that high-quality population-based data
on birth prevalence and pregnancy outcomes are readily avail-
able in settings with rigorous surveillance programmes, which
provide information on congenital malformations. However,
not all countries have yet established robust surveillance sys-
tems and, for these countries, methods are needed to generate
estimates of prevalence of these disorders which can act as a
starting point for assessing disease burden and service impli-
cation (Blencowe et al. 2017; Moorthie et al. 2017). In this
paper, which is the 5th in a supplement on the estimation of
congenital disorders, we describe how data from the European
Surveillance of Congenital Anomalies and Twins
(EUROCAT) network can be used both to obtain country-
specific rates for birth prevalences and outcomes and to gen-
erate average European rates for use as reference rates for
countries with little or no observational data on non-
syndromic congenital malformations.
Congenital malformations are structural abnormalities of
prenatal origin and can be classified into three groups based
on their cause: genetic, environmental or multifactorial
(Czeizel 2005). The precise cause of many malformations that
fall under the multifactorial group is unknown; however, they
are thought to be due to interactions between genetic and
environmental factors (Czeizel 2005; EUROCAT 2004;
Kurnit et al. 1987). In MGDb, congenital malformations are
bundled as far as possible according to underlying cause.
Malformations caused by known environmental exposures
(e.g. teratogens including maternal infections) are treated sep-
arately. Malformations associated with chromosomal disor-
ders are treated as part of the relevant chromosomal syndrome,
and malformations associated with single gene disorders, ge-
netic syndromes or parental consanguinity are grouped as
inherited disorders. These steps leave a large group of congen-
ital malformations with multifactorial or unknown cause. In
MGDb, this group is modelled under the heading of non-
syndromic congenital malformations (NSCM), as they are
not associated with any known primary environmental or ge-
netic syndrome.Malformations that affect only one system are
called isolated malformations; malformations involving more
than one system are called multiple malformations.
As our primary data source is EUROCAT, we have follow-
ed EUROCAT classification in our methodology. Thus, iso-
lated malformations are classified as those that include more
than one malformation from the same body system and se-
quences, included in this are single malformations (e.g. cleft
lip), more than one malformations from the same system (e.g.
VSD and coarctation and more than one malformation as part
of a sequence (e.g. spina bifida with talipes) (EUROCAT
2013). Malformations that are not classified as above and
involve more than one system fall under the multiple malfor-
mation group.
Description of data source
EUROCAT is our principal source for the baseline epidemiol-
ogy of congenital malformations because it collects data from
numerous registries in European countries with advanced di-
agnostic facilities. The network includes registries that submit
raw data which is analysed centrally and associate registries
that submit aggregated data. Special reports, details of
methods used and lists of publications are available via the
EUROCAT website. In brief, data are collected on all major
structural congenital anomalies, chromosomal anomalies,
syndromes and other hereditary conditions that are associated
with structural anomalies. Registration covers affected live
births, foetal deaths after 20-week gestation and termination
of pregnancy for foetal anomaly following prenatal diagnosis.
There is variation between registries on the age up to which
new cases are ascertained; however, the majority of registries
ascertain cases up to at least 1 year of life (Boyd et al. 2011).
EUROCAT publishes detailed downloadable data on the
web (EUROCAT). It is possible to request specific data; how-
ever, we have restricted ourselves to using the publicly avail-
able downloadable data. This is in order to develop a method-
ology that can be easily replicated by public health and policy-
makers, utilising readily accessible data sources.
This data set was chosen as it contains standardised, com-
prehensive information from a range of countries on all major
congenital malformations. The countries providing data have
advanced facilities for diagnosis and data collection, including
multiple sources (often linked) such as specialist databases for
individual malformations, hospital admissions and discharge
records, plus foetal neonatal and child pathology reports
allowing for good ascertainment. EUROCAT has developed
a number of strategies to ensure data quality, including the
development of data quality indicators (DQIs) which can be
compared with EUROCAT average rates to evaluate factors
such as ascertainment, accuracy of diagnosis, completeness of
information, availability of denominator information and
timeliness of data transmission (Loane et al. 2011). Our eval-
uation of the data from EUROCAT shows that although there
is variation in the reported prevalence rate between registries,
rates from each registry are consistent over time, which may
reflect differences in the pattern of data collection. Some inter-
country variation is due to real differences in prevalence, for
example, the higher prevalence of neural tube defects in
Northern and Eastern Europe and orofacial clefts in
Scandinavian populations that has been previously reported
(Khoshnood et al. 2015; Mossey and Modell 2012).
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Data
Only data from the registries that are full EUROCATmembers
and therefore submit raw, un-aggregated data were included in
the analysis. Some registries in countries where termination of
pregnancy (TOPFA) is legal do not report terminations, and
this would lead to under-ascertainment of total birth preva-
lence. We therefore exclude data from these registries. In ad-
dition, when estimating average rates for termination of preg-
nancy, we excluded data from Ireland and Malta where
TOPFA is illegal.
EUROCAT prevalence tables available online provide infor-
mation on the number of cases of all congenital malformations
either including or excluding cases with a known genetic condi-
tion, and the population denominator by year; the numbers of
affected births and birth outcomes (live birth, foetal death, termi-
nation for foetal anomaly). These data are further broken down to
provide the number of cases under 11 system groups (e.g. ner-
vous system, eye, congenital heart defects etc.) and diagnoses
under these system groups (e.g. neural tube defect, congenital
glaucoma, severe CHD); diagnoses relating to certain environ-
mental causes (e.g. foetal alcohol syndrome, maternal infections
resulting in malformations) and the number of cases of chromo-
somal disorders, which is further broken down by specific diag-
nosis (Down syndrome, Patau etc.). Each case appears only once
in each system group, but cases with malformations affecting
more than one system group appear in more than one system
sub-group.
Data for the years 1980–2012, by country, for all congen-
ital malformations excluding cases with known genetic con-
ditions were downloaded (Bnon-genetic^ cases) (EUROCAT).
Birth prevalence and birth outcome rates were calculated as
the number of cases per 1000 total births, with the denomina-
tor being the total births covered by the registry. Foetal deaths,
defined as losses after 20 weeks of pregnancy, are used cau-
tiously as a proxy for stillbirths in MGDb. In estimating birth
outcome rates in MGDb, it is important to estimate the foetal
death rate in the absence of any intervention as this provides
the baseline situation allowing assessment of the impact of
interventions, and also enables estimation for countries with
limited or no access to prenatal diagnosis. TOPFA is common
in most countries participating in EUROCAT, and hence the
foetal death rate was calculated as foetal deaths per 1000
Bcontinuing pregnancies^ (i.e. per 1000 pregnancies that have
not been terminated). Average European rates were derived
from an unweighted average of country-specific rates.
Calculating average global reference rates
for non-syndromic congenital malformations
& Step 1: Calculating rates of non-syndromic congenital
malformations (NSCM)
Data for the Bnon-genetic^ group provide the total sum of
individuals with congenital malformations including congen-
ital malformations associated with other syndromes/anoma-
lies, or with environmental causes. The total numbers of indi-
viduals with NSCM were obtained by subtracting cases that
were present in the Bother anomalies/syndromes subgroup^
from the EUROCAT total for individuals with Bnon-genetic^
malformations. This consisted of cases present in the follow-
ing sub-groups: teratogenic syndromes with malformations,
skeletal dysplasias, situs inversus, craniosyntosis, congenital
constriction bands/amniotic band, conjoined twins, congenital
skin disorders, VATER/VACTERL, vascular disruption
anomalies and lateral anomalies. We have assumed that each
case represents one individual for these sub-groups (Fig. 1).
Details of the rates in these groups can be found in Web ap-
pendix Table 1.
The data were aggregated into 5-year groups in order to
relate it to World Population Prospects (WPP) (United
Nations Population Division) demographic data, and the evo-
lution of rates for each system sub-group and totals were ex-
amined. This led to the selection of the 2000–2009 interval for
calculation of the average European baseline birth prevalence,
because it provides the most stable data in relation to birth
prevalence. The spread of routine foetal anomaly scanning
led to a gradual rise in the reporting of birth prevalences of
some congenital disorders from 1980 to around 2000 (Fig. 1,
Web appendix). Data from the most recent 5-year period are
not included as they were incomplete (at the time the data was
downloaded, 2012 was the latest year reported). The
EUROCATaverage for TOPFA is based on rates over the time
period 2000–2009 by 5-year intervals.
& Step 2: Country-specific rates for non-syndromic congen-
ital malformations
The above process was applied to country-specific data to
obtain country-specific rates for NSCM. Table 1 shows the
total prevalence rates for NSCM in 2000–2009, with countries
ranked in descending order of total reported birth prevalence.
Although there are substantial inter-country differences, indi-
vidual country rates have remained relatively stable over time.
Higher than average rates are reported from a number of
countries, most of them in Northern Europe. A higher preva-
lence of neural tube defects in Northern and Eastern Europe
and of orofacial clefts in Scandinavian populations (with
Finland a very significant outlier for cleft palate) may be partly
responsible, as also may inclusion of a higher proportion of
less severe congenital heart defects in some registers. Most of
the remaining differences appear to be due to differences in
ascertainment. Under-ascertainment is considered likely if a
registry reports less than 20/1000 total congenital anomalies
(EUROCAT 2011), which corresponds to around 17/1000
Bnon-genetic^ anomalies. Using this criterion, under-
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ascertainment may be suspected in Croatia, Italy, Spain and
Portugal (Table 1).
& Step 3: Calculating baseline rates by system group
The pregnancy outcomes may vary depending on the
type of malformation (i.e. system group affected) and if
it was isolated or associated with malformations in other
systems. Consequently, baseline prevalence by system
group is valuable in assessing outcomes. EUROCAT
data available publically on the Internet (EUROCAT)
only relate to non-syndromic congenital malformations
by system group, meaning that individuals with more
than one malformation are represented multiple times.
A data request could have been made directly to
EUROCAT for this data. However, in order to use the
publically available data to obtain rates for affected in-
dividuals by system group, we needed to estimate what
proportion of individuals had an isolated malformation
(not associated with a malformation in another system),
and to add a Bmultiple malformation^ group. This was
done in three steps.
& Estimate proport ion of isolated and mult iple
malformations
The proportion of NSCM that was isolated and the propor-
tion that contributed tomultiple malformations were estimated
by comparing births of affected individuals with the total sum
of the number of malformations across all the systems groups
(Table 2). The difference between these totals is an indicator
of the frequency of multiple malformations. Overall, 19.56
[95% CI 19.47, 19.56] per 1000 births are affected by non-
syndromic malformations, whereas the sum of malformations
by system group is 20.21 [95% CI 20.12, 20.3] per 1000
births. The difference between the two (2.8/1000) represents
the frequency of multiple malformations.
& Estimate the baseline prevalence rate for multiple malfor-
mation group
α Malformations associated with chromosomal and single gene disorders e.g. Down 
syndrome, microdeletions and genetic syndromes
β Malformations primarily attributed to environmental factors (e.g. congenital rubella 
syndrome, fetal alcohol syndrome)
γ Associated with rare syndromes or other conditions (e.g. Craniosynostosis,cojoined 
twins)
Δ Includes malformations with multi-factorial or unknown primary cause
Congenital 
malformations
27.0/1000
Genetic α
4.0/1000
Environmental β
0.32/1000
Non-syndromic δ
21.2/1000
Non-genetic
23.0/1000
Miscellaneous γ
1.5/1000
Isolated 
malformations
19.8/1000
Multiple 
malformations
1.4/1000
Fig. 1 Calculating rates for non-syndromic congenital malformations
from EUROCAT data. Main groups of congenital malformations
included in congenital anomaly registries participating in EUROCAT
(average total prevalence rates/1000, 2000–2009) are shown below.
Rates for non-syndromic congenital malformations were calculated by
subtracting cases attributable to environmental factors and associated
with other rare syndromes from total non-genetic cases> non-syndromic
congenital malformation
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To derive a baseline prevalence rate for the multiple mal-
formation group, we used an average of estimated rates report-
ed in the literature. Average reported rates include: 1.27 /1000
reported by Rittler et al. (2008), 1.59/1000 reported by Garne
et al. (2011) and 1.58 reported by Calzolari et al. (2014).
Slightly lower rates of 1.08/1000 for multiple malformations,
with 12.7% foetal deaths and 27% terminations of pregnancy
were reported by Tennant et al. (2010): however, this report
excludes most genital and limb malformations and covered a
period (1985–2003) when prenatal diagnosis was evolving. In
MGDb, we use 1.41/1000 multiple malformations as it is an
average of the reported rates in the literature (Garne et al.
2011; Rittler et al. 2008).
& Calculating rates for isolated malformations by system
group
In order to obtain rates for isolated malformations by sys-
tem group, the proportion within each malformation group
contributing to multiple malformations needed to be assessed
and rates adjusted accordingly. EUROCAT non-syndromic
total births/1000 were adjusted using the percentage reported
in the literature to be associated with other malformations.
Published association rates from Garne et al. (2011) supple-
mented by rates from Rittler et al. (2008) were used to esti-
mate within each system group, those which are isolated and
those which contribute to multiple malformations. Table 3
shows the percentage associated with other malformations
for each system group and the adjusted baseline birth preva-
lence rates by malformation group.
Estimating birth outcome rates for isolated
malformations
Data are available in the EUROCAT database for outcomes of
affected pregnancies for all non-syndromic malformations
combined. We adjusted outcome rates for isolated and multi-
ple malformations in the same way as for calculating birth
prevalences, assuming that isolated malformations accounted
for 86.15% of live births, 65.01% of terminations and 64.87%
of foetal deaths (Table 2). Table 4 shows the resulting esti-
mates for isolated malformations by system group. We have
done this in the absence of more refined data. As pregnancy
outcomes may vary depending on the type of defect (i.e.
Table 2 Non-syndromic malformations by system group, birth prevalences and birth outcomes 2000–2009 inclusive (data downloaded Jan 2015)
Malformation group Rates /1000 [95% CI] Foetal death % of
pregnancies intended
to continueLive births Fetal deaths TOPFA Total affected births
Neural tube defects (NTD) 0.26 [0.25,0.27] 0.04 [0.04,0.04] 0.65 [0.63,0.67] 0.95 [0.93,0.97] 13.33
Central nervous system not NTD 0.86 [0.84,0.88] 0.04 [0.04,0.04] 0.35 [0.34,0.36] 1.25 [1.23,1.27] 4.44
Eye 0.38 [0.37,0.39] 0.01 [0.01,0.01] 0.04 [0.04,0.04] 0.43 [0.42,0.44] 2.56
Ear, face and neck 0.31 [0.3,0.32] 0.01 [0.01,0.01] 0.05 [0.05,0.05] 0.37 [0.36,0.38] 3.13
Congenital heart defects 6.59 [6.54,6.64] 0.07 [0.06,0.08] 0.37 [0.36,0.38] 7.03 [6.98,7.08] 1.05
Respiratory 0.26 [0.25,0.27] 0.03 [0.03,0.03] 0.11 [0.1,0.12] 0.4 [0.39,0.41] 10.34
Oro-facial clefts 1.25 [1.23,1.27] 0.02 [0.02,0.02] 0.11 [0.1,0.12] 1.38 [1.36,1.4] 1.57
Digestive system 1.42 [1.4,1.44] 0.04 [0.04,0.04] 0.17 [0.16,0.18] 1.63 [1.6,1.66] 2.74
Abdominal wall defects 0.33 [0.32,0.34] 0.02 [0.02,0.02] 0.16 [0.15,0.17] 0.51 [0.5,0.52] 5.71
Urinary 2.78 [2.75,2.81] 0.05 [0.05,0.05] 0.37 [0.36,0.38] 3.2 [3.16,3.24] 1.77
Genital 1.99 [1.96,2.02] 0.01 [0.01,0.01] 0.07 [0.06,0.08] 2.07 [2.04,2.1] 0.50
Limb 3.78 [3.74,3.82] 0.06 [0.06,0.07] 0.29 [0.28,0.3] 4.13 [4.09,4.17] 1.56
Total sum of malformations 20.21 [20.12,20.3] 0.4 [0.39,0.41] 2.96 [2.93,2.99] 23.57 [23.47,23.67] 1.94
Rate for individuals with
non-syndromic malformations
17.41 [17.33,17.49] 0.26 [0.25,0.27] 1.92 [1.90,1.95] 19.56 [19.47,19.65] 1.45
Difference between total sum and
rate for individuals with NSCM
2.8 [2.77,2.83] 0.14 [0.13,0.15] 1.04 [1.02,1.06] 3.98 [3.94,4.02]
Individuals with isolated malformations,
% of system sum
86.15 [86.12,86.17] 65.01 [64.51,65.5] 64.87 [64.68,65.05] 83.11 [83.08,83.15]
TOPFA: termination of pregnancy for foetal anomaly,
NSCM: non-syndromic congenital malformation,
NTD: neural tube defects,
CI: confidence interval
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system group affected), this may result in under/over estima-
tion of outcomes for certain system sub-groups.
Foetal deaths are difficult to estimate due to possible under-
ascertainment and their relationship to TOPFA. We have as-
sumed that the foetal death rates calculated as a proportion of
continuing pregnancies are unlikely to be greatly affected by
differences in the level of pregnancy care. However, this
method may lead to under-estimation of foetal death in the
absence of care, because the most severe cases are both most
likely to be detected on prenatal ultrasound scan with many
families opting for termination of pregnancy based on predict-
ed poor outcomes, and more likely to result in foetal death in
Table 3 Adjusted baseline rates for different malformation groups. Baseline rates were adjusted based on association rates obtained from Garne et al.
2011, supplemented with data from Rittler et al. 2008 (shown in italics)
Group EUROCAT non-syndromic
total births/1000
Per cent associated with other
malformations
Total births, isolated
malformations/1000
Total births, non-isolated
malformations/1000
Non-syndromic malformations 19.56 [19.47,19.65] 18.40 1.41
Neural Tube Defects (NTD) 0.95 [0.93,0.97] 13.00 0.83 0.12
Central nervous system not NTD 1.25 [1.23,1.27] 23.50 0.96 0.29
Eye 0.43 [0.42,0.44] 24.40 0.33 0.10
Ear, face and neck 0.37 [0.36,0.38] 38.10 0.23 0.14
Congenital heart defectsa 7.03 [6.98,7.08] 11.00 6.26 0.77
Respiratory 0.4 [0.39,0.41] 11.70 0.35 0.05
Oro-facial cleftsa 1.38 [1.36,1.4] 15.50 1.17 0.21
Digestive system 1.63 [1.6,1.66] 29.90 1.14 0.49
Abdominal wall defects 0.51 [0.5,0.52] 14.20 0.44 0.07
Urinary 3.2 [3.16,3.24] 10.70 2.86 0.34
Genital 2.07 [2.04,2.1] 12.80 1.81 0.26
Limb 4.13 [4.09,4.17] 11.00 3.68 0.45
a Country-specific rates were used NTDs and orofacial clefts in MGDb, rates were obtained from registries or the published literature. European average
rates were calculated for congenital heart defects using data from a EUROCAT special report on CHD
Table 4 Adjusted rates for outcomes of different malformation groups.
The approximate distribution of birth outcomes for isolated congenital
malformation groups was calculated from rates for non-syndromic
malformation groups assuming that isolated malformations account for
86.15% of live births, 65.01% of terminations and 64.87% of foetal
deaths
Malformation group Non-syndromic/1000 Isolated/1000
Total Live births Foetal deaths TOPFA Total Live births Foetal deaths TOPFA Foetal death % of
pregnancies intended
to continue
Births with non-syndromic
malformations
19.8 17.9 0.25 1.66 1.45
Births with multiple malformations 1.41 0.97 0.07 0.37 7.0
Neural tube defects (NTD) 0.95 0.26 0.04 0.65 0.83 0.22 0.03 0.42 10.37
Central nervous system not NTD 1.25 0.86 0.04 0.35 0.97 0.74 0.03 0.23 3.38
Eye 0.43 0.38 0.01 0.04 0.33 0.33 0.01 0.03 1.94
Ear, face and neck 0.37 0.31 0.01 0.05 0.23 0.27 0.01 0.03 2.37
Congenital heart defects 7.03 6.59 0.07 0.37 6.26 5.69 0.05 0.24 0.79
Respiratory 0.4 0.26 0.03 0.11 0.35 0.22 0.02 0.07 7.99
Oro-facial clefts 1.38 1.25 0.02 0.11 1.17 1.08 0.01 0.07 1.19
Digestive system 1.63 1.42 0.04 0.17 1.14 1.23 0.03 0.11 2.08
Abdominal wall defects 0.51 0.33 0.02 0.16 0.44 0.29 0.01 0.10 4.36
Urinary 3.2 2.78 0.05 0.37 2.86 2.40 0.03 0.24 1.34
Genital 2.07 1.99 0.01 0.07 1.81 1.72 0.01 0.05 0.38
Limb 4.13 0.29 0.06 3.78 3.68 0.19 0.04 3.27 1.18
TOPFA termination of pregnancy for foetal anomaly
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the absence of termination of pregnancy. EUROCAT country
rates for total foetal deaths for non-genetic conditions are
shown in Table 5. Countries are ranked in descending order
of foetal deaths/1000 births. As can be seen, there are wide
inter-country differences. The high rate reported fromUkraine
reflects persisting high prevalence of neural tube defects, but
this does not apply for other countries. If inter-country differ-
ences were due to selective termination of pregnancies other-
wise most likely to end in foetal death, it would be expected
that the foetal death rate would fall as rate for termination of
pregnancy rises. However, the very weak relationship be-
tween the two (web appendix Fig. 2) suggests under-
ascertainment of termination of pregnancy and/or foetal
deaths in some registries as the likely explanation for most
of the inter-country differences.
Strengths and limitation of European
reference rates
Using publically available EUROCAT data to obtain reference
rates has a number of strengths including representation of a
wide range of countries across Europe, participating countries
having advanced facilities for diagnosis and data collection,
collection of data on a wide range of disorders in a
standardised manner and reporting of all pregnancy outcomes
including foetal death and elective termination of pregnancy
for foetal anomaly.
From a practical view, data accessibility and the distinction
of congenital malformations by cause, further enable ease of
use for this purpose. However, there are limitations, with in-
dividual registries differing in case ascertainment due to a
number of factors (e.g. resources, extent, amount of prenatal
diagnosis available to women, number of data sources used
and mode of access to records etc.). This is particularly likely
for outcomes that end in a foetal loss or termination of preg-
nancy and this may partially account for considerable differ-
ences between countries in reported rates. Nevertheless, the
large number of participating registries tends to reduce inter-
country biases when calculating European averages. Many of
these limitations could have been overcome by requesting
data directly from EUROCAT and using the EUROCAT data
quality indicators (Loane et al. 2011) to only select those reg-
isters that have good ascertainment and high-quality data.
The differential contribution of country data to EUROCAT
can affect calculated European averages as countries with par-
ticularly high or low recorded rates could significantly skew
the average, e.g. the inclusion of registries that do not report
Table 5 Non-genetic congenital
malformations. Foetal death rates
by country, ranked in descending
order of % of continuing
pregnancies. Data source:
EUROCAT 2000–2009
Country Foetal deaths/1000 Foetal deaths % of total Foetal deaths % of
continuing pregnancies
Ukraine 0.80 3.64 4.19
Ireland 0.58 3.43 3.43
Malta 0.57 2.14 2.14
United Kingdom 0.48 2.44 2.81
Denmark 0.43 1.77 1.93
Germany 0.43 1.37 1.46
Finland (assoc) 0.43 1.14 1.21
Netherlands 0.35 1.67 1.74
Belgium 0.31 1.51 1.64
Switzerland 0.30 0.97 1.06
Austria 0.29 0.98 1.03
France 0.26 1.28 1.51
Norway 0.21 0.68 0.73
Croatia 0.17 1.07 1.13
Portugal 0.15 1.66 1.79
Spain 0.11 0.97 1.04
Czech Rep (assoc) 0.11 0.34 0.39
Poland 0.10 0.66 0.66
Hungary 0.09 0.35 0.37
Italy 0.07 0.44 0.50
Sweden (assoc) 0.05 0.29 0.32
Average for full registries
TOP legal reported
0.26 1.30 1.40
*assoc: associated registry
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terminations of pregnancy would falsely reduce average rates
whereas the inclusion of countries where termination of preg-
nancy is illegal or not reported would reduce estimated aver-
age rates for termination of pregnancy. We have attempted to
control for the impact of TOPFA, by excluding countries that
do not report on this subject and exclude countries where
TOPFA is illegal when looking at pregnancy outcomes.
We also tested the potential effect of differences in population
size on the country rates by adjusting the rates in Table 2 using
World Population Prospects (WPP) annual births data. The re-
sult was an increase of approximately 5% in average baseline
birth prevalence, a 9% increase in terminations and a 6% in-
crease in foetal deaths (see web appendix Table 2). In principle,
these rates could be used to adjust average EUROCAT rates.
However, no adjustment is currently made, in order to minimise
complication in the methodology and to remain as close as
possible to the primary data. Furthermore, this may lead to
over-estimation of the results which we wished to avoid.
It is recognised that a large proportion of congenital
malformations have an unknown cause (Feldkamp et al. 2017).
The diversity and relatively constant birth prevalence of these
unexplainedmalformations suggest that many are due to random
accidents during the complex process of embryonic develop-
ment, a concept that is supported bymathematical considerations
(Kurnit et al. 1987). There have been few global studies carrying
out detailed comparisons of rates in populations with different
ethnicities. Studies have been carried out in the United States and
Europe report ethnic differences in neural tube defects, orofacial
clefts, thyroid a/dysplasia and polydactyly (Bundey and Alam
1993; Chitty and Winter 1989; Egbe 2015). In addition,
EUROCAT rates for France include data from congenital anom-
aly registries in Martinique, Guadeloupe and Reunion, all with
predominantly non-European populations, reported rates are sim-
ilar to those for metropolitan France. Due to limited evidence to
indicate significant country differences in birth prevalence of
these disorders (apart from neural tube defects and orofacial
clefts), robust data from high-income countries could be applied
to those where there is a lack of data to obtain provisional
estimates.
Apart from folic acid supplementation or food fortification
(which is not yet policy in most of Europe), the main inter-
vention likely to cause true inter-country variation in the ob-
served birth prevalence of congenital malformations is the
level of access to prenatal diagnosis with the option of termi-
nation of pregnancy. The birth prevalence rates developed
here can be used as provisional estimates for the overall base-
line prevalence of certain congenital malformations and for
estimating the proportions of each malformation group that
end in termination of pregnancy or foetal death.
Other sources of data including the International Clearing
house for Birth Defect Surveillance and Research (ICBDSR)
and National Birth Defects Prevention Network (NBDPN)
were also assessed for potential inclusion. An advantage of
ICBDSR is that it includes a spectrum from non-European
countries. However, ICBDSR includes data from a diverse
range of data systems and there is less consistency in data
collection across programmes that contribute to ICBDSR, this
can lead to under-ascertainment (see Table 3 web appendix).
Detailed data from NBDPN is not available online; further-
more, analysis of available data suggests that the reported rates
are higher than EUROCAT (Web appendix Table 4). In the
interests of providing a conservative estimate, we have
employed data from EUROCAT. In addition, the relative
standardisation of EUROCAT data was an advantage.
EUROCATaverages provide a useful baseline for policy and
planning purposes for most non-syndromic malformations in
countries where high-quality registry data are not yet available.
However, ethnic and environmental factors affect the birth prev-
alence of some groups of non-syndromic malformations, includ-
ing neural tube defects and orofacial clefts. For these conditions,
local or regional information on prevalence where available is
preferable to EUROCAT averages, and EUROCAT and
ICBDSR country-specific data has been used in MGDb (Kadir
et al. 2016). Our aim was to enable non-specialist policy makers
to develop estimates; hence, we have developed methods that
rely on readily accessible data sources. These estimates can be
improved on and can be done so through direct contact with data
sources such as EUROCAT to obtain more precise breakdowns.
Conclusion
Accurately assessing the prevalence of pregnancies and births
affected by congenital malformations requires clinical exper-
tise, advanced diagnostic techniques including routine foetal
anomaly scanning and availability of perinatal/paediatric post-
mortem examination, coupled with medically certified registra-
tion of cause of death and robust reporting to dedicated
population-based congenital anomaly registers. These re-
sources are not available in the majority of countries outside
Europe and North America. In these countries, diagnosis fre-
quently relies primarily on physical examination, with only
around 30% of congenital malformations can be reliably diag-
nosed (Neel 1958; Todros et al. 2001). In addition, where avail-
able registries are usually hospital-based and cover the first few
days of life only, thus limiting prevalence rate estimates.
Based on our analysis of EUROCAT registry data, there is
limited evidence to indicate significant country differences in
the baseline birth prevalence of non-syndromic congenital
malformations, other than neural tube defects and orofacial
clefts. We therefore propose the use of methods based on rates
observed in high-income European settings, to obtain provi-
sional global, regional and country estimates for the birth
prevalence of these malformation groups in settings with no
data, as a starting point. These methods do not provide precise
estimates, but those that may be sufficient for policy and
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programmatic purposes, until robust data become available for
all settings; which is only possible through dedicated and sus-
tainable surveillance systems. Many WHO regions including
South East Asia, Africa and Latin America have recognised
this issue and are working to develop capacity in this area as
part of their framework for the prevention and control of birth
defects (Flores et al. 2015; WHO Regional Office for South
East Asia; WHO Regional Office for South East Asia 2013).
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